Chemed Corporation (CHE) is a publicly traded Healthcare sector company. As of October 27, 2026, CHE trades at $506.43 with a market cap of $6.70B and a P/E ratio of 25.55. CHE moved -0.74% today. Year to date, CHE is +20.13%; over the trailing twelve months it is +16.56%. Its 52-week range spans $365.21 to $623.61. Analyst consensus is buy with an average price target of $584.50. Rallies surfaces CHE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Chemed Q3 adjusted EPS beats estimates as VITAS growth lifts revenue: Chemed’s Q3 revenue rose 10.6% to $690.90 million and adjusted EPS climbed 28.1% to $6.75, beating analyst estimates. Roto-Rooter reacquired California franchise territories for approximately $62.5 million, covering more than 12 million people.
| Metric | Value |
|---|---|
| Price | $506.43 |
| Market Cap | $6.70B |
| P/E Ratio | 25.55 |
| EPS | $19.90 |
| Dividend Yield | 0.70% |
| 52-Week High | $623.61 |
| 52-Week Low | $365.21 |
| Volume | 157.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.60B |
| Net Income | $274.99M |
| Gross Margin | 33.11% |
4 analysts cover CHE: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $584.50.